The average one-year price target for Spruce Biosciences (NasdaqCM:SPRB) has been revised to $235.11 / share. This is an ...

Spruce Biosciences, Inc. (SPRB) could be a solid choice for investors given its recent upgrade to a Zacks Rank #2 (Buy). This rating change essentially reflects an upward trend in earnings estimates - ...

Shares of Spruce Biosciences, Inc. (SPRB) have been struggling lately and have lost 43.2% over the past four weeks. However, a hammer chart pattern was formed in its last trading session, which could ...

The average one-year price target for Spruce Biosciences (NasdaqCM:SPRB) has been revised to $137.19 / share. This is an increase of 2,045.14% from the prior estimate of $6.40 dated November 7, 2025.

Short interest in Spruce Biosciences Inc (NASDAQ:SPRB) increased during the last reporting period, rising from 107.07K to 444.88K. This put 1.14% of the company's publicly available shares short.

Data is not available at this time. Insider Trading information for NDAQ is derived from Forms 3 and 4 filings filed with the U.S. Securities and Exchange Commission (SEC). Please Note:An FPI is ...

Spruce Biosciences Inc. Annual cash flow by MarketWatch. View SPRB net cash flow, operating cash flow, operating expenses and cash dividends.